Overview

Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

Status:
Not yet recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.
Phase:
Phase 2
Details
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.